<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="87510">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02116751</url>
  </required_header>
  <id_info>
    <org_study_id>EC 039/14</org_study_id>
    <nct_id>NCT02116751</nct_id>
  </id_info>
  <brief_title>Frequency and Clinical Significance of Renal and Bone Toxicity in HIV-infected Patients</brief_title>
  <acronym>ComorVIH</acronym>
  <official_title>Frequency and Clinical Significance of Renal and Bone Toxicity in HIV-infected Patients: Role of Classical Factors, HIV Infection, and Antiretroviral Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asociacion para el Estudio de las Enfermedades Infecciosas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asociacion para el Estudio de las Enfermedades Infecciosas</source>
  <oversight_info>
    <authority>Spain: Agencia Espa√±ola de Medicamentos y Productos Sanitarios</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the frequency of renal and bone toxicity in HIV
      infected patients receiving antiretroviral therapy, and the outcome in terms of treatment
      change or/and virological failure, in relation with the presence of classical factors, such
      as diabetes or hypertension, the role of HIV itself, because of chronic inflammation, and
      the effects of antiretroviral medication.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a retrospective cohort study involving 300 patients to determine the frequency of
      renal and bone comorbidities/toxicity in a large population of HIV-infected patients
      receiving antiretroviral therapy, in order to establish the differential role of classical
      factors, HIV infection, or antiretroviral therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Incidence of Renal and Bone toxicity</measure>
    <time_frame>Patients will be evaluated for 2 years before</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number and percentage of patients with:
Confirmed estimated glomerular filtration rate (eGFR) by CKD (chronic kidney disease)-epi equation decrease to &lt; 60 ml/min, or/and
More than 25% of eGFR decrease during therapy, or/and
Tubular toxicity defined as at least two of confirmed proteinuria (&gt; 300 mg/g), glycosuria with euglycemia, fractional excretion of urinary phosphate &gt; 20%, or of uric acid &gt; 10%. AND
Number and percentage of patients with bone mineral density (BMD) decrease &gt; 10% during follow up or progression to osteopenia (from normal) or to osteoporosis (from osteopenia)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Consequences of renal or bone toxicity</measure>
    <time_frame>Patients will be evaluated for 2 years before</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Percentage of patients with regimen discontinuation (any drug in the regimen) because of renal or/and bone toxicity</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in renal and bone toxicity</measure>
    <time_frame>2 years before entry</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Evolution of renal and bone parameters in case of regimen discontinuation</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Renal Toxicity</condition>
  <eligibility>
    <study_pop>
      <textblock>
        HIV infected patients in active follow up, receiving antiretroviral therapy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed HIV infection

        Exclusion Criteria:

          -  Pregnancy

          -  Prior therapy with antineoplastic chemotherapy or chronic treatment with
             corticosteroids

          -  Previous chronic therapy with antiresorptive bone therapy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose L Casado, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ramon y Cajal Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jose L Casado, MD</last_name>
    <phone>34913368672</phone>
    <email>jcasado.hrc@salud.madrid.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ramon y Cajal Hospital</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose L Casado, MD</last_name>
      <phone>34913368672</phone>
      <email>jcasado.hrc@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jose L Casado, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 15, 2014</lastchanged_date>
  <firstreceived_date>April 11, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV, antiretroviral, toxicity, eGFR, tubular involvement, BMD</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
